Header Logo

Connection

KENNETH R HESS to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications KENNETH R HESS has written about Antineoplastic Agents.
KENNETH R HESS
Connection Strength
0.626
Antineoplastic Agents
  1. Clinical importance of eflornithine (a-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018 04; 7(2):CNS16.
    View in: PubMed
    Score: 0.127
  2. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106.
    View in: PubMed
    Score: 0.061
  3. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
    View in: PubMed
    Score: 0.035
  4. Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology. 1998 Apr; 50(4):1197; disscussion 1197-8.
    View in: PubMed
    Score: 0.032
  5. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
    View in: PubMed
    Score: 0.032
  6. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.030
  7. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215.
    View in: PubMed
    Score: 0.029
  8. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
    View in: PubMed
    Score: 0.025
  9. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8.
    View in: PubMed
    Score: 0.024
  10. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393.
    View in: PubMed
    Score: 0.020
  11. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.018
  12. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Mol Cancer. 2009 Nov 10; 8:99.
    View in: PubMed
    Score: 0.018
  13. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15.
    View in: PubMed
    Score: 0.016
  14. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6.
    View in: PubMed
    Score: 0.016
  15. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
    View in: PubMed
    Score: 0.015
  16. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 01; 24(25):4107-15.
    View in: PubMed
    Score: 0.014
  17. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006 May 03; 98(9):625-36.
    View in: PubMed
    Score: 0.014
  18. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
    View in: PubMed
    Score: 0.013
  19. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
    View in: PubMed
    Score: 0.013
  20. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
    View in: PubMed
    Score: 0.013
  21. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
    View in: PubMed
    Score: 0.010
  22. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001 Feb 15; 91(4):815-21.
    View in: PubMed
    Score: 0.010
  23. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.009
  24. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 1996 Sep; 2(9):1489-97.
    View in: PubMed
    Score: 0.007
  25. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
    View in: PubMed
    Score: 0.007
  26. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8.
    View in: PubMed
    Score: 0.006
  27. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014 Mar; 19(3):228-34.
    View in: PubMed
    Score: 0.006
  28. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.